The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -8,169 | -26,095 |
| Depreciation and amortization | 105 | 274 |
| Accretion of debt discount and debt issuance costs | 249 | 465 |
| Stock-based compensation expense | 2,420 | 8,085 |
| Allowance (benefit) for credit losses | -33 | 61 |
| Provision (benefit) for excess and obsolete inventories | 21 | -24 |
| Noncash operating lease expense | 127 | 241 |
| Loss on disposal of property and equipment | -4 | - |
| Noncash loss on debt extinguishment | 0 | 0 |
| Accounts receivable | 98 | -1,112 |
| Inventory | 1,791 | -135 |
| Prepaid expenses and other current assets | 1,127 | -201 |
| Other noncurrent assets | 207 | -73 |
| Accounts payable | -335 | 385 |
| Accrued compensation | 965 | -4,453 |
| Accrued and other current liabilities | -850 | 392 |
| Other noncurrent liabilities | 0 | 0 |
| Net cash used in operating activities | -8,719 | -19,148 |
| Purchases of property and equipment | 170 | 210 |
| Net cash used in investing activities | -170 | -210 |
| Net proceeds from hercules loan agreement | 0 | 0 |
| Repayment of prior loan agreement | 0 | 0 |
| Debt issuance costs | 0 | 0 |
| Proceeds from employee stock purchase plan purchases | -1 | 434 |
| Taxes paid on net share settlement of restricted stock units | -1 | -54 |
| Proceeds from exercise of common stock options | 27 | 121 |
| Net cash provided by (used in) financing activities | 25 | 501 |
| Net change in cash, cash equivalents, and restricted cash | -8,864 | -18,857 |
| Cash and cash equivalents at beginning of period | 120,357 | - |
| Cash and cash equivalents at end of period | 92,636 | - |
Sight Sciences, Inc. (SGHT)
Sight Sciences, Inc. (SGHT)